XML 47 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Jan. 31, 2013
Jan. 31, 2012
Jan. 31, 2011
Cash flows from operating activities      
Net income $ 56,569 $ 49,620 $ 56,682
Adjustments to reconcile net income to net cash provided by (used) in operating activities, net of assets and liabilities acquired:      
Depreciation and amortization 9,941 7,473 5,733
Equity based compensation 7,738 5,200 3,314
Tax benefit from exercise/vesting of equity awards 1,378 809  
Deferred financing charges 500 425 844
Equity loss in joint venture 719 1,271  
Deferred income taxes (1,191) 3,568 6,125
Gain on sale of joint venture interest (185)    
Changes in operating assets and liabilities:      
Accounts receivable, net (8,249) (24,169) (64,885)
Inventories (16,862) (48,526) (85,118)
Income taxes, net 6,114 6,171 (10,833)
Prepaid expenses and other current assets (3,824) (1,324) (2,935)
Other assets, net (2,833) 64 (1,055)
Accounts payable, accrued expenses and other liabilities 4,679 6,194 63,479
Net cash provided by (used in) operating activities 54,494 6,776 (28,649)
Cash flows from investing activities      
Acquisition of Vilebrequin, net of cash acquired (80,252)    
Proceeds from (investment in) equity of joint venture, net 1,885 (3,650)  
Capital expenditures (11,615) (17,410) (19,407)
Net cash used in investing activities (89,982) (21,060) (19,407)
Cash flows from financing activities      
Proceeds from notes payable, net 34,950 30,050  
Noncontrolling interest investment, net (883)    
Loss attributable to noncontrolling interest 306    
Proceeds from exercise of stock warrants     4,129
Proceeds from exercise of equity awards 1,425 619 2,786
Stock repurchase   (2,929)  
Excess tax benefit from exercise/vesting of equity awards 1,870 1,136 4,356
Net cash provided by financing activities 37,668 28,876 11,271
Foreign currency translation adjustments 520 23 17
Net increase (decrease) in cash and cash equivalents 2,700 14,615 (36,768)
Cash and cash equivalents at beginning of year 24,660 10,045 46,813
Cash and cash equivalents at end of year 27,360 24,660 10,045
Cash paid during the year for:      
Interest 9,996 5,228 4,145
Income taxes 28,615 18,243 36,548
Notes issued in connection with the acquisition of Vilebrequin 19,778    
Contingent consideration in connection with the acquisition of Vilebrequin $ 5,787